Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

Maternal and Fetal Factors Affecting Cell-Free Fetal DNA (cffDNA) Fraction: A Systematic Review

Authors
Majid Zaki-Dizaji 1
Arman Shafiee 2
Omid Kohandel Gargari 3
Haniyeh Fathi 2
Zohreh Heidary 4
1 Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
2 Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
3 Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karachi, Iran
4 Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran
10.18502/jri.v24i4.14149
Abstract
Background: Cell-free fetal DNA (cffDNA) is a novel screening method for fetal aneuploidy that facilitated non-invasive prenatal testing (NIPT) through analysis of cffDNA in maternal plasma. However, despite increased sensitivity, it has a number of limitations that may complicate of its results interpretation. Therefore, elucidating factors affecting fetal fraction, as a critical limitation, guides its clinical application. Methods: In this report, systematic search was carried out through PubMed, Web of Science, and Scopus databases until February 11, 2022 by using keywords consist of "noninvasive prenatal screening", "NIPT", "noninvasive prenatal", "cell free DNA" and "fetal fraction". The jri_articles were screened for eligibility criteria before data extraction. Results: A total of 39 eligible studies, most published between 2010 and 2020, were included. Based on the results of studies, a negative correlation between maternal age and BMI/body weight with fetal fraction was found. Furthermore, LDL, cholesterol, triglyceride level, metformin, heparin and enoxaparin therapy, hemoglobin-related hemoglobinopathies, and physical activity showed to have negative associations. Interestingly, it seems the ethnicity of patients from South and East Asia has a correlation with fetal fraction compared to Caucasians. Positive correlation was observed between gestational age, free β-hCG, PAPP-A, living in high altitude, and twin pregnancy. Conclusion: Considering each factor, there was significant inconsistency and controversy regarding their impact on outcomes. Indeed, multiple factors can influence the accuracy of NIPS results, and it is worth noting that the impact of these factors may vary depending on the individual’s ethnic background. Therefore, it is important to recognize that NIPS remains a screening test, and comprehensive pre- and post-NIPS counseling should be conducted as part of standard clinical practice.
Keywords
cell
free DNA
Fetal fraction
gestational age
maternal age
Non
invasive prenatal testing
  1. Warsof SL, Larion S, Abuhamad AZ. Overview of the impact of noninvasive prenatal testing on diagnostic procedures. Prenat Diagn. 2015;35(10):972-9.
  2. van der Meij KRM, Sistermans EA, Macville MVE, Stevens SJC, Bax CJ, Bekker MN, et al. TRIDENT-2: National implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in the Netherlands. Am J Hum Genet. 2019;105(6):1091-101.
  3. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485-7.
  4. Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017;50(3):302-14.
  5. Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing. Clin Chem. 2010;56(8):1279-86.
  6. Chan KCA, Zhang J, Hui ABY, Wong N, Lau TK, Leung TN, et al. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem. 2004;50(1):88-92.
  7. Alberry M, Maddocks D, Jones M, Abdel Hadi M, Abdel-Fattah S, Avent N, et al. Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast. Prenat Diagn. 2007;27(5):415-8.
  8. Scott FP, Menezes M, Palma-Dias R, Nisbet D, Schluter P, da Silva Costa F, et al. Factors affecting cell-free DNA fetal fraction and the consequences for test accuracy. J Matern Fetal Neonatal Med. 2018;31(14):1865-72.
  9. Illanes S, Denbow M, Kailasam C, Finning K, Soothill PW. Early detection of cell-free fetal DNA in maternal plasma. Early Hum Dev. 2007;83(9):563-6.
  10. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999;64(1):218-24.
  11. Guy GP, Hargrave J, Dunn R, Price K, Short J, Thilaganathan B. Secondary non-invasive prenatal screening for fetal trisomy: an effectiveness study in a public health setting. BJOG. 2021;128(2):440-6.
  12. Fiorentino F, Bono S, Pizzuti F, Mariano M, Polverari A, Duca S, et al. Response to "the importance of determining the limit of detection of non-invasive prenatal testing methods". Prenatal Diagn. 2016;36(9):898-9.
  13. Scheffer PG, Wirjosoekarto SAM, Becking EC, Weiss MM, Bax CJ, Oepkes D, et al. Association between low fetal fraction in cell-free DNA testing and adverse pregnancy outcome: a systematic review. Prenatal Diagn. 2021;41(10):1287-95.
  14. Deng C, Liu S. Factors affecting the fetal fraction in noninvasive prenatal screening: a review. Front Pediatr. 2022;10:812781.
  15. Mousavi S, Shokri Z, Bastani P, Ghojazadeh M, Riahifar S, Nateghian H. Factors affecting low fetal fraction in fetal screening with cell-free DNA in pregnant women: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2022;22(1):918.
  16. Deng C, Liu J, Liu S, Liu H, Bai T, Jing X, et al. Maternal and fetal factors influencing fetal fraction: A retrospective analysis of 153,306 pregnant women undergoing noninvasive prenatal screening. Front Pediatr. 2023;11:1066178.
  17. Santoro G, Lapucci C, Giannoccaro M, Caporilli S, Rusin M, Seidenari A, et al. Abnormal circulating maternal miRNA expression is associated with a low (<4%) cell-free DNA fetal fraction. Diagnostics (Basel). 2021;11(11):2108.
  18. Dolatkhah M, Rahnamaye Farzami M, Khavari-Nejad R-A, Noori SJIJoNI. Correlation of maternal age, weight, pregnancy-associated plasma protein a, free beta-human chorionic gonadotropin, fetal crown-rump length, and fetal gender with fetal DNA fraction in non-invasive prenatal testing: an experiment on Iranian pregnant women. Iran J Neonatol. 2021;12(1):26-32.
  19. Talbot AL, Ambye L, Hartwig TS, Werge L, Sørensen S, Stormlund S, et al. Fetal fraction of cell-free DNA in pregnancies after fresh or frozen embryo transfer following assisted reproductive technologies. Hum Reprod. 2020;35(6):1267-75.
  20. Serapinas D, Boreikaitė E, Bartkevičiūtė A, Norvilaitė K, Narbekovas A, Bartkevičienė DJM. The level of free fetal DNA as precise noninvasive marker for chromosomal aneuploidies: first results from BALTIC region. medicina (Kaunas). 2020;56(11):579.
  21. Miltoft CB, Rode L, Bundgaard JR, Johansen P, Tabor A. Cell-free fetal DNA in the early and late first trimester. Fetal Diagn Ther. 2020;47(3):228-36.
  22. Lopes JL, Lopes GS, Enninga EAL, Kearney HM, Hoppman NL, Rowsey RA. Most noninvasive prenatal screens failing due to inadequate fetal cell free DNA are negative for trisomy when repeated. Prenat Diagn. 2020;40(7):831-7.
  23. Zhao Q, HuoJiaBieKe J, Du SJJoGO, Reproduction H. The influence of fetal gender and maternal characteristics on fetal cell-free DNA in maternal plasma. J Gynecol Obstet Hum Reprod. 2019;48(8):653-656.
  24. Qiao L, Yu B, Liang Y, Zhang C, Wu X, Xue Y, et al. Sequencing shorter cfDNA fragments improves the fetal DNA fraction in noninvasive prenatal testing. Am J Obstet Gynecol. 2019;221(4):345.e1-345.e11.
  25. Hou Y, Yang J, Qi Y, Guo F, Peng H, Wang D, et al. Factors affecting cell-free DNA fetal fraction: statistical analysis of 13,661 maternal plasmas for non-invasive prenatal screening. Hum Genomics. 2019;13(1):62.
  26. Guo FF, Yang JX, Huang YL, Qi YM, Hou YP, Peng HS, et al. Association between fetal fraction at the second trimester and subsequent spontaneous preterm birth. Prenat Diagn. 2019;39(13):1191-7.
  27. Rolnik DL, da Silva Costa F, Lee TJ, Schmid M, McLennan ACJUiO, Gynecology. Association between fetal fraction on cell‐free DNA testing and first‐trimester markers for pre‐eclampsia. Ultrasound Obstet Gynecol. 2018;52(6):722-7.
  28. Miltoft CB, Rode L, Ekelund CK, Sundberg K, Kjaergaard S, Zingenberg H, et al. Contingent first‐trimester screening for aneuploidies with cell‐free DNA in a Danish clinical setting. Ultrasound Obstet Gynecol. 2018;51(4):470-9.
  29. Sarno L, Revello R, Hanson E, Akolekar R, Nicolaides KH. Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy. Ultrasound Obstet Gynecol. 2016;47(6):705-11.
  30. Revello R, Sarno L, Ispas A, Akolekar R, Nicolaides KH. Screening for trisomies by cell‐free DNA testing of maternal blood: consequences of a failed result. Ultrasound Obstet Gynecol. 2016;47(6):698-704.
  31. Krishna I, Badell M, Loucks TL, Lindsay M, Samuel A. Adverse perinatal outcomes are more frequent in pregnancies with a low fetal fraction result on noninvasive prenatal testing. Prenat Diagn. 2016;36(3):210-5.
  32. Zhou Y, Zhu Z, Gao Y, Yuan Y, Guo Y, Zhou L, et al. Effects of maternal and fetal characteristics on cell-free fetal DNA fraction in maternal plasma. Reprod Sci. 2015;22(11):1429-35.
  33. Ashoor G, Syngelaki A, Poon L, Rezende JC, Nicolaides KH. Fetal fraction in maternal plasma cell‐free DNA at 11–13 weeks' gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013;41(1):26-32.
  34. Suzumori N, Ebara T, Yamada T, Samura O, Yotsumoto J, Nishiyama M, et al. Fetal cell-free DNA fraction in maternal plasma is affected by fetal trisomy. J Hum Genet. 2016;61(7):647-52.
  35. Rava RP, Srinivasan A, Sehnert AJ, Bianchi DW. Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. Clin Chem. 2014;60(1):243-50.
  36. Wang E, Batey A, Struble C, Musci T, Song K, Oliphant A. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013;33(7):662-6.
  37. Poon LCY, Musci T, Song K, Syngelaki A, Nicolaides KH. Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks' gestation: relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn Ther. 2013;33(4):215-23.
  38. Lee TJ, Rolnik DL, Menezes MA, McLennan AC, da Silva Costa F. Cell-free fetal DNA testing in singleton IVF conceptions. Hum Reprod. 2018;33(4):572-8.
  39. Kuhlmann‐Capek M, Chiossi G, Singh P, Monsivais L, Lozovyy V, Gallagher L, et al. Effects of medication intake in early pregnancy on the fetal fraction of cell‐free DNA testing. Prenat Diagn. 2019;39(5):361-8.
  40. Kinnings SL, Geis JA, Almasri E, Wang H, Guan X, McCullough RM, et al. Factors affecting levels of circulating cell‐free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing. Prenat Diagn. 2015;35(8):816-22.
  41. Hedriana H, Martin K, Saltzman D, Billings P, Demko Z, Benn P. Cell-free DNA fetal fraction in twin gestations in single-nucleotide polymorphism-based noninvasive prenatal screening. Prenat Diagn. 2020;40(2):179-84.
  42. Cao J, Qiao L, Jin J, Zhang S, Chen P, Tang H, et al. Lipid metabolism affects fetal fraction and screen failures in non-invasive prenatal testing. Front Med (Lausanne). 2021;8:811385.
  43. Burns W, Koelper N, Barberio A, Deagostino‐Kelly M, Mennuti M, Sammel MD, et al. The association between anticoagulation therapy, maternal characteristics, and a failed cfDNA test due to a low fetal fraction. Prenat Diagn. 2017;37(11):1125-9.
  44. Bevilacqua E, Gil MM, Nicolaides KH, Ordoñez E, Cirigliano V, Dierickx H, et al. Performance of screening for aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies. Ultrasound Obstet Gynecol. 2015;45(1):61-6.
  45. Tarquini F, Picchiassi E, Centra M, Pennacchi L, Galeone F, Bini V, et al. Maternal smoking does not affect the amount of cell-free fetal DNA in maternal plasma during the 1st trimester of pregnancy. J Obstet Gynaecol. 2015;35(1):42-5.
  46. Hopkins MK, Koelper N, Bender W, Durnwald C, Sammel M, Dugoff L. Association between cell‐free DNA fetal fraction and gestational diabetes. Prenat Diagn. 2020;40(6):724-7.
  47. Nakamura N, Sasaki A, Mikami M, Nishiyama M, Akaishi R, Wada S, et al. Nonreportable rates and cell‐free DNA profiles in noninvasive prenatal testing among women with heparin treatment. Prenat Diagn. 2020;40(7):838-45.
  48. Putra M, Idler J, Patek K, Contos G, Walker C, Olson D, et al. The association of HBB-related significant hemoglobinopathies and low fetal fraction on noninvasive prenatal screening for fetal aneuploidy. J Maten Fetal Neonatal Med. 2021;34(22):3657-61.
  49. Schlütter JM, Hatt L, Bach C, Kirkegaard I, Kølvraa S, Uldbjerg N. The cell‐free fetal DNA fraction in maternal blood decreases after physical activity. Prenat Diagn. 2014;34(4):341-4.
  50. Zhong XY, Wang Y, Chen S, Pan X, Zhu N, Hahn C, et al. Circulating fetal DNA in maternal plasma is increased in pregnancies at high altitude and is further enhanced by preeclampsia. Clin Chem. 2004;50(12):2403-5.
  51. Vora NL, Johnson KL, Basu S, Catalano PM, Hauguel-De Mouzon S, Bianchi DW. A multifactorial relationship exists between total circulating cell-free DNA levels and maternal BMI. Prenat Diagn. 2012;32(9):912-4.
  52. van Kleffens M, Groffen C, Lindenbergh-Kortleve DJ, van Neck JW, González-Parra S, Dits N, et al. The IGF system during fetal-placental development of the mouse. Mol Cell Endocrinol. 1998;140(1-2):129-35.
  53. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA. 1999;96(6):3149-53.
  54. Irwin JC, Suen LF, Martina NA, Mark SP, Giudice LC. Role of the IGF system in trophoblast invasion and pre-eclampsia. Hum Reprod. 1999;14 Suppl 2:90-6.
  55. Conover CA, Bale LK, Overgaard MT, Johnstone EW, Laursen UH, Füchtbauer EM, et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development. 2004;131(5):1187-94.
  56. Hahn S, Rusterholz C, Hösli I, Lapaire O. Cell-free nucleic acids as potential markers for preeclampsia. Placenta. 2011;32 Suppl:S17-20.
  57. Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1998;105(6):632-40.
  58. Slonim DK, Koide K, Johnson KL, Tantravahi U, Cowan JM, Jarrah Z, et al. Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc Natl Acad Sci. 2009;106(23):9425-9.
  59. Muchová J, Žitňanová I, Ďuračková Z. Oxidative stress and Down syndrome. Do antioxidants play a role in therapy? Physiol Res. 2014;63(5):535-42.
  60. Wataganara T, LeShane ES, Farina A, Messerlian GM, Lee T, Canick JA, et al. Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. Hum Genet. 2003;112(2):204-8.
  61. Lee DE, Lim JH, Kim MH, Park SY, Ryu HM. Novel epigenetic markers on chromosome 21 for noninvasive prenatal testing of fetal trisomy 21. J Mol Diagn. 2016;18(3):378-87.
  62. Lim JH, Kim SY, Park SY, Lee SY, Kim MJ, Han YJ, et al. Non-invasive epigenetic detection of fetal trisomy 21 in first trimester maternal plasma. PLoS One. 2011;6(11):e27709.
  63. Bahado-Singh R, Friedman P, Talbot C, Aydas B, Southekal S, Mishra NK, et al. Cell-free DNA in maternal blood and artificial intelligence: accurate prenatal detection of fetal congenital heart defects. Am J Obstet Gynecol. 2023;228(1):76.e1-76.e10.
  64. Chen M, Jiang F, Guo Y, Yan H, Wang J, Zhang L, et al. Validation of fetal DNA fraction estimation and its application in noninvasive prenatal testing for aneuploidy detection in multiple pregnancies. Prenat Diagn. 2019;39(13):1273-82.
  65. Zhong XY, Bürk MR, Troeger C, Jackson LR, Holzgreve W, Hahn SJPd. Fetal DNA in maternal plasma is elevated in pregnancies with aneuploid fetuses. Prenat Diagn. 2000;20(10):795-8.
  66. Alberry MS, Maddocks DG, Hadi MA, Metawi H, Hunt LP, Abdel-Fattah SA, et al. Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol. 2009;200(1): 98.e1-6.
Journal of Reproduction & Infertility
Volume 24, Issue 4
Autumn 2023
Pages 219-231